Managing occluded stents in biliary obstruction using radiofrequency ablation combined with125i-strand brachytherapy

Abstract

PURPOSE We aimed to assess the effectiveness of percutaneous radiofrequency ablation (PRFA) combined with iodine-125 (125 I) seed strand brachytherapy (125 I-BT) for treatment of occluded biliary stents. METHODS From November 2015 to September 2017, 13 consecutive patients with occluded biliary metal stents, implanted for malignant obstruction, underwent PRFA combined with125I-BT to reopen the bile duct. Data included clinical and technical success, stent patency, complications, and overall survival. RESULTS The clinical and technical success rates were both 100%. One month after treatment, the total serum bilirubin level had decreased significantly (p < 0.001). Early complications of cholangi-tis or hemobilia were experienced by one patient each. Three patients (23.1%) had late com-plications, including two cases of cholangitis and one case of cholecystitis. During the mean follow-up of 233±82.9 days (range, 88–365 days), the stent patency time was 239±26.5 days (95% CI, 187–291 days), and the 6-month stent patency rate was 68.4%. Five patents died; the mean survival time was 298±30.1 days (95% CI, 239–358 days). The 6-month survival rate was 83%. CONCLUSION PRFA therapy combined with125I-BT is feasible and safe for patients with occluded metal stents placed for malignant biliary obstruction. Nevertheless, randomized controlled trails are needed to confirm the effectiveness of this new approach.